Danaher (DHR) Stock Price, News & Analysis

Company Overview

Danaher is a global science and technology company that develops and supplies products and services for biotechnology, life sciences, and diagnostics markets. Its offerings include instruments, reagents, consumables, software, and services used in research, drug development and manufacturing, and clinical testing.

The company’s businesses include well-known brands such as Cytiva and Pall in bioprocessing and filtration, Beckman Coulter in laboratory and clinical diagnostics, Cepheid in molecular diagnostics, and Leica Microsystems in microscopy. Danaher serves customers in healthcare, pharmaceutical and biotechnology, academic, and research markets around the world.

Founded in 1969 and headquartered in Washington, D.C., Danaher has grown through acquisitions and portfolio changes. It applies its Danaher Business System, a set of management and continuous-improvement practices, across its operating companies. Rainer M. Blair has served as the company’s president and chief executive officer since 2020.

Key Stats

• Today's Range: $222.96 to $230.66
• 50-Day Range: $200.30 to $236.77
• 52-Week Range: $160.93 to $242.80
• Volume: 4.06 million shs
• Average Volume: 4.50 million shs
• Market Capitalization: $162.05 billion
• P/E Ratio: 37.70
• Dividend Yield: 0.69%
• Price Target: $242.91
• Consensus Rating: Moderate Buy

Danaher Stock Analysis - MarketRank™

Danaher scored higher than 82% of companies evaluated by MarketBeat, and ranked 53rd out of 886 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Danaher has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on no strong buy ratings, 18 buy ratings, 5 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Danaher is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Danaher has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 8.38%

Earnings Growth

Earnings for Danaher are expected to grow by 8.38% in the coming year, from $8.59 to $9.31 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Danaher is 37.70, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.50.

Price to Earnings Ratio vs. Sector

The P/E ratio of Danaher is 37.70, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.54.

Price to Earnings Growth Ratio

Danaher has a PEG Ratio of 2.86. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Danaher has a P/B Ratio of 3.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.30% of the float of Danaher has been sold short.

Short Interest Ratio / Days to Cover

Danaher has a short interest ratio ("days to cover") of 1.91, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Danaher has recently decreased by 9.21%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Danaher has a dividend yield of 0.70%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Danaher has only been increasing its dividend for 2 years.

Dividend Coverage

The dividend payout ratio of Danaher is 26.19%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Danaher will have a dividend payout ratio of 17.19% next year. This indicates that Danaher will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 1.17

News Sentiment

Danaher has a news sentiment score of 1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 23 news articles for Danaher this week, compared to 9 articles on an average week.

Search Interest

Only 14 people have searched for DHR on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.

MarketBeat Follows

11 people have added Danaher to their MarketBeat watchlist in the last 30 days. This is an increase of 83% compared to the previous 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Danaher insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,782,187.00 in company stock.

Percentage Held by Insiders

10.80% of the stock of Danaher is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

79.05% of the stock of Danaher is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 10/30 Dividend: 9/30/2026
• Ex-Dividend for 10/30 Dividend: 9/30/2026
• Last Earnings: 10/21/2026
• Dividend Payable: 10/30/2026
• Today: 11/07/2026
• UBS Global Healthcare Conference: 11/09/2026
• Jefferies Global Healthcare Conference: 11/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NYSE:DHR
• CIK: 313616
• Web: www.danaher.com
• Phone: (202) 828-0850
• Fax: 202-828-0860
• Employees: 60,000
• Year Founded: 1984

Price Target and Rating

• Average Price Target for Danaher: $242.91
• High Price Target: $275.00
• Low Price Target: $195.00
• Potential Upside/Downside: +5.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 23 Analysts

Profitability

• EPS (Trailing Twelve Months): $6.11
• Trailing P/E Ratio: 37.70
• Forward P/E Ratio: 24.74
• P/E Growth: 2.86
• Net Income: $3.61 billion
• Net Margins: 16.91%
• Pretax Margin: 18.81%
• Return on Equity: 11.17%
• Return on Assets: 6.71%

Debt

• Debt-to-Equity Ratio: 0.45
• Current Ratio: 1.63
• Quick Ratio: 1.29

Sales & Book Value

• Annual Sales: $24.57 billion
• Price / Sales: 6.60
• Cash Flow: $11.49 per share
• Price / Cash Flow: 20.05
• Book Value: $76.23 per share
• Price / Book: 3.02

Miscellaneous

• Outstanding Shares: 703,530,000
• Free Float: 627,550,000
• Market Cap: $162.05 billion
• Optionable: Optionable
• Beta: 0.76